Equity Details
Price & Market Data
Price: $24.63
Daily Change: +$0.10 / 0.41%
Daily Range: $23.46 - $24.95
Market Cap: $863,348,736
Daily Volume: 206,867
Performance Metrics
1 Week: -3.22%
1 Month: -4.35%
3 Months: 47.93%
6 Months: 113.3%
1 Year: 952.6%
YTD: 38.37%
About Alto Neuroscience, Inc. (ANRO)
Market summary for Alto Neuroscience, Inc. (ANRO). Price: 24.63, daily change: +$0.10 / 0.41%. Market cap: 863,348,736. Performance YTD, 1-month, 3-month.
Company Details
Employees: 68
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.